The World Orphan Drug Congress in Brussels in November was the another conference Partners4Access attended. This year’s agenda focused on the challenges orphan drug manufacturers are facing in the regulatory and HTA environment. Topics as “value for money of orphan medicines” is a challenge our clients are facing every day. High profile health economists discussed ways towards a fair and sustainable, innovative orphan drug industry that ensures the collaboration between all stakeholders to provide access for patients. Hearing the speakers confirmed that P4A is going in the right direction. Our vision is ensuring fair access for all key stakeholders fair access to drugs for rare disease patients, fair value for those that fund treatments, access to the smartest clinical option for the disease expert and a fair return on investment for the orphan drug manufacturer.
Partners4Access will continue its exchange with high profile experts in the field of orphan diseases and market access, to ensure consistent delivery of excellence for our clients. If you would like to meet us at one of the next conferences, please get in touch.
Partners4Access is a global consultancy 100% focused on orphan drug access.
The company support the biotechnology and pharmaceutical industry along their launch journey to help secure successful price, reimbursement and access for orphan drugs. Partners4Access has solid partnerships with clients supporting their strategy and operations to effectively ensure launch success.